科研製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2022/03/11 | 4,160 | 4,185 | 4,135 | 4,135 | -75 | -1.8% | 60,900 |
| 2022/03/10 | 4,190 | 4,220 | 4,160 | 4,210 | +75 | +1.8% | 109,600 |
| 2022/03/09 | 4,100 | 4,145 | 4,100 | 4,135 | +5 | +0.1% | 77,600 |
| 2022/03/08 | 4,125 | 4,155 | 4,110 | 4,130 | +10 | +0.2% | 103,400 |
| 2022/03/07 | 4,110 | 4,125 | 4,085 | 4,120 | +5 | +0.1% | 68,200 |
| 2022/03/04 | 4,130 | 4,180 | 4,115 | 4,115 | -50 | -1.2% | 53,800 |
| 2022/03/03 | 4,105 | 4,195 | 4,105 | 4,165 | +70 | +1.7% | 75,300 |
| 2022/03/02 | 4,130 | 4,155 | 4,090 | 4,095 | -105 | -2.5% | 122,400 |
| 2022/03/01 | 4,240 | 4,250 | 4,195 | 4,200 | -20 | -0.5% | 51,500 |
| 2022/02/28 | 4,135 | 4,230 | 4,135 | 4,220 | +115 | +2.8% | 55,000 |
| 2022/02/25 | 4,165 | 4,190 | 4,085 | 4,105 | -45 | -1.1% | 38,500 |
| 2022/02/24 | 4,100 | 4,160 | 4,080 | 4,150 | +30 | +0.7% | 45,000 |
| 2022/02/22 | 4,120 | 4,140 | 4,105 | 4,120 | -20 | -0.5% | 55,200 |
| 2022/02/21 | 4,160 | 4,165 | 4,120 | 4,140 | -75 | -1.8% | 44,800 |
| 2022/02/18 | 4,215 | 4,240 | 4,180 | 4,215 | +10 | +0.2% | 36,300 |
| 2022/02/17 | 4,300 | 4,305 | 4,200 | 4,205 | -100 | -2.3% | 46,600 |
| 2022/02/16 | 4,305 | 4,320 | 4,280 | 4,305 | +65 | +1.5% | 66,000 |
| 2022/02/15 | 4,250 | 4,275 | 4,220 | 4,240 | +5 | +0.1% | 51,100 |
| 2022/02/14 | 4,180 | 4,240 | 4,140 | 4,235 | +40 | +1% | 72,800 |
| 2022/02/10 | 4,160 | 4,205 | 4,160 | 4,195 | +35 | +0.8% | 98,200 |
| 2022/02/09 | 4,160 | 4,170 | 4,140 | 4,160 | +20 | +0.5% | 59,300 |
| 2022/02/08 | 4,125 | 4,170 | 4,125 | 4,140 | +35 | +0.9% | 59,000 |
| 2022/02/07 | 4,070 | 4,130 | 4,070 | 4,105 | +10 | +0.2% | 64,300 |
| 2022/02/04 | 4,105 | 4,115 | 4,050 | 4,095 | -95 | -2.3% | 91,900 |
| 2022/02/03 | 4,200 | 4,225 | 4,180 | 4,190 | -10 | -0.2% | 58,300 |
| 2022/02/02 | 4,150 | 4,210 | 4,140 | 4,200 | +55 | +1.3% | 52,100 |
| 2022/02/01 | 4,100 | 4,175 | 4,095 | 4,145 | +45 | +1.1% | 57,000 |
| 2022/01/31 | 4,180 | 4,180 | 4,085 | 4,100 | -105 | -2.5% | 92,100 |
| 2022/01/28 | 4,210 | 4,230 | 4,185 | 4,205 | +60 | +1.4% | 61,300 |
| 2022/01/27 | 4,195 | 4,215 | 4,125 | 4,145 | -25 | -0.6% | 88,100 |
| 2022/01/26 | 4,240 | 4,240 | 4,160 | 4,170 | -55 | -1.3% | 53,800 |
| 2022/01/25 | 4,215 | 4,260 | 4,195 | 4,225 | -50 | -1.2% | 66,300 |
| 2022/01/24 | 4,180 | 4,280 | 4,180 | 4,275 | +40 | +0.9% | 75,800 |
| 2022/01/21 | 4,215 | 4,235 | 4,175 | 4,235 | +25 | +0.6% | 71,300 |
| 2022/01/20 | 4,230 | 4,275 | 4,195 | 4,210 | -15 | -0.4% | 92,700 |
| 2022/01/19 | 4,220 | 4,260 | 4,210 | 4,225 | -35 | -0.8% | 87,100 |
| 2022/01/18 | 4,330 | 4,335 | 4,245 | 4,260 | -40 | -0.9% | 58,300 |
| 2022/01/17 | 4,295 | 4,345 | 4,270 | 4,300 | -20 | -0.5% | 50,000 |
| 2022/01/14 | 4,255 | 4,320 | 4,245 | 4,320 | +65 | +1.5% | 88,100 |
| 2022/01/13 | 4,255 | 4,270 | 4,220 | 4,255 | +10 | +0.2% | 62,200 |
| 2022/01/12 | 4,205 | 4,260 | 4,205 | 4,245 | +40 | +1% | 58,200 |
| 2022/01/11 | 4,195 | 4,230 | 4,180 | 4,205 | +50 | +1.2% | 55,100 |
| 2022/01/07 | 4,180 | 4,210 | 4,140 | 4,155 | -35 | -0.8% | 62,300 |
| 2022/01/06 | 4,190 | 4,240 | 4,190 | 4,190 | -10 | -0.2% | 45,100 |
| 2022/01/05 | 4,230 | 4,230 | 4,195 | 4,200 | -45 | -1.1% | 55,300 |
| 2022/01/04 | 4,220 | 4,255 | 4,210 | 4,245 | +35 | +0.8% | 55,600 |
| 2021/12/30 | 4,250 | 4,250 | 4,210 | 4,210 | -55 | -1.3% | 47,100 |
| 2021/12/29 | 4,240 | 4,295 | 4,240 | 4,265 | +45 | +1.1% | 55,200 |
| 2021/12/28 | 4,180 | 4,230 | 4,170 | 4,220 | +35 | +0.8% | 41,600 |
| 2021/12/27 | 4,200 | 4,200 | 4,170 | 4,185 | -30 | -0.7% | 26,800 |
801～
850
件表示中 / 3723件
類似銘柄と比較する
現在ご覧いただいている「科研薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 科研薬 | 386,000円 | -6.4% | -71.8% | 4.92% | 43.11倍 | 0.96倍 |
|
旧理研グループの名門。導入の関節機能改善剤、自社創製の爪白癬症薬の２本柱。後発品も展開 |
| ジーエヌアイ | 378,000円 | +21.7% | +999.9% | 0.00% | 15.84倍 | 5.24倍 |
|
中国の特発性肺線維症で高シェア、肺線維症後続薬進出。米国で人工骨も。米中に研究開発機能 |
| 鳥居薬 | 634,000円 | +7.1% | -35.0% | 0.00% | 52.43倍 | 1.47倍 |
|
ＪＴ傘下。柱の抗ＨＩＶ薬販売権喪失後、自社製品の腎・透析、アレルゲン等の開発強化 |
| 東和薬品 | 299,900円 | +7.9% | -3.3% | 2.67% | 8.34倍 | 0.86倍 |
|
後発医薬品メーカーで国内２強の一角。循環器系に強い。直販軸に発展も卸との取引を拡大中 |
| ゼリア新薬 | 203,900円 | +3.1% | -6.5% | 2.35% | 9.46倍 | 1.00倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
市場注目の銘柄
チャート関連のコラム
